$UNCY News
Last published 3w ago
- 3w agoUNCYUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027GlobeNewswireResubmission includes Chemistry, Manufacturing, and Controls (CMC) data from new drug product (DP) manufacturing vendor MOUNTAIN VIEW, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.
- 3w agoUNCYINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Unicycive Therapeutics, Inc. to Contact Law FirmPR NewswireUnicycive Therapeutics, Inc. (NASDAQ:UNCY) shareholders should email fletcher@fmoorelaw.comNEW YORK, Oct. 20, 2026 /PRNewswire/ -- What is the
- 1mo agoUNCYKirby McInerney LLP Alerts Investors Who Acquired Unicycive Therapeutics, Inc. UNCY Securities Between December 29, 2025 and June 29, 2026 of Pending LawsuitGlobeNewswireNEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY) investors of the November 2, 2026 deadline to seek the
- 2mo agoUNCYUNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff RoleBusiness WireIf you have suffered a loss on your Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at
- 2mo agoUNCYUnicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireLOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or
- 3mo agoUNCYUnicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor - FDA has assigned a facility inspection to
- 4mo agoUNCYUNCY ALERT: Unicycive Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Encouraged to Contact the FirmGlobeNewswireBOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ:UNCY) for potential securities law violations. Investors who have lost money in their Unicycive
- 4mo agoUNCYUnicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)GlobeNewswire-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor -- -- FDA inspection of third-party facility did not occur during the NDA resubmission review -- --
- 6mo agoUNCYUnicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireU.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29,
- 7mo agoUNCYKuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ:...
- 7mo agoUNCYUnicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireLOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or
- 7mo agoUNCYUnicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireOxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial
- 8mo agoITGRMOHUNCYWBTNImportant Notice to Long-Term Shareholders of Integer Holdings Corp. (NYSE: ITGR): Molina Healthcare, Inc. (NYSE: MOH); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corp. (NYSE:ITGR): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Integer Holdings Corp. (NYSE:ITGR). The
- 8mo agoBSXCORTNKTRUNCYImportant Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 10, 2026 (GLOBE NEWSWIRE) -- Boston Scientific Corporation (NYSE:BSX): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Boston Scientific Corporation
- 8mo agoCORTKDMOHUNCYImportant Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Corcept Therapeutics, Inc. (NASDAQ:CORT): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Corcept Therapeutics, Inc.
- 9mo agoUNCYUnicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech SummitGlobeNewswireLOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or
- 9mo agoUNCYUPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) ResubmissionGlobeNewswireFDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) --
- 9mo agoUNCYUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) ResubmissionGlobeNewswireDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) --
- 10mo agoUNCYUnicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)GlobeNewswireLOS ALTOS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney
- 11mo agoCYTKFTREUNCYWBTNImportant Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ:CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ:CYTK). The investigation concerns
- 11mo agoUNCYUnicycive Therapeutics to Participate in Upcoming Investor Events in DecemberGlobeNewswireLOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or
- 12mo agoAVTRFIVEMSSUNCYImportant Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); Five Below, Inc. (NASDAQ: FIVE); Maison Solutions Inc. (NASDAQ: MSS); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA , Nov. 14, 2025 (GLOBE NEWSWIRE) -- Avantor, Inc. (NYSE:AVTR): Grabar Law Office is investigating claims on behalf of shareholders of Avantor, Inc. (NYSE:AVTR). The investigation concerns whether
- 12mo agoUNCYUnicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire- Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC
- 1y agoAVTRFIVEMOHUNCYImportant Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); Five Below, Inc. (NASDAQ: FIVE); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Avantor, Inc. (NYSE:AVTR): Grabar Law Office is investigating claims on behalf of shareholders of Avantor, Inc. (NYSE:AVTR). The investigation concerns whether certain
- 1y agoUNCYUnicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswireLOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or
- 1y agoUNCYUnicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 ConferenceGlobeNewswireLOS ALTOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or
- 1y agoUNCYUnicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-EndGlobeNewswireLOS ALTOS, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the Company or Unicycive),
- 1y agoUNCYUNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses in Unicycive
- 1y agoUNCYSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UnicycivePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or...
- 1y agoAMLXHUMUNCYVSTSAttention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX): Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) as
- 1y agoHUMJSPRUNCYVSTSImportant Notice to Long-Term Shareholders of Humana Inc. (NYSE: HUM); Jasper Therapeutics, Inc. (NASDAQ: JSPR); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humana Inc. (NYSE:HUM): Grabar Law Office is investigating claims on behalf of shareholders of Humana Inc. (NYSE:HUM). The investigation concerns whether certain
- 1y agoUNCYUNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UnicyciveGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities
- 1y agoUNCYSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UnicycivePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or...
- 1y agoUNCYINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses in Unicycive
- 1y agoUNCYShareholders of Unicycive Therapeutics, Inc. Should Contact The Gross Law Firm Before October 14, 2025 to Discuss Your Rights – UNCYGlobeNewswireNEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY).
- 1y agoUNCYSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options If you suffered
- 1y agoUNCYShareholders of Unicycive Therapeutics, Inc. Should Contact The Gross Law Firm Before October 14, 2025 to Discuss Your Rights – UNCYGlobeNewswireNEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ:UNCY). Shareholders who purchased shares of UNCY during the class
- 1y agoUNCYShareholders of Unicycive Therapeutics, Inc. Should Contact The Gross Law Firm Before October 14, 2025 to Discuss Your Rights - UNCYPR NewswireThe Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of...
- 1y agoUNCYINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or...
- 1y agoUNCYInvestors in Unicycive Therapeutics, Inc. Should Contact The Gross Law Firm Before October 14, 2025 to Discuss Your Rights - UNCYPR NewswireThe Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of...
- 1y agoUNCYINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or...
- 1y agoUNCYUnicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 14, 2025 to Discuss Your Rights – UNCYGlobeNewswireNEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ:UNCY). Shareholders who purchased shares of UNCY during the class
- 1y agoUNCYShareholders of Unicycive Therapeutics, Inc. Should Contact The Gross Law Firm Before October 14, 2025 to Discuss Your Rights – UNCYGlobeNewswireNEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ:UNCY). Shareholders who purchased shares of UNCY during the class
- 1y agoUNCYINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or...
- 1y agoUNCYUnicycive Therapeutics to Participate in Upcoming Investor Events in SeptemberGlobeNewswireLOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or
- 1y agoUNCYSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities
- 1y agoUNCYSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsBusiness WireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options If you suffered
- 1y agoUNCYUnicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney DiseaseGlobeNewswireLOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or
- 1y agoUNCYUnicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire- Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) - OLC pivotal study data, published in the Clinical Journal
- 1y agoUNCYUnicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of NephrologyGlobeNewswireLOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or